The NR1D subgroup of orphan NRs, Rev-erbα (NR1D1) and Rev-erbβ (NR1D2)
======================================================================

All members of the NR superfamily display a highly conserved structural organisation with an amino terminal AB region (that encodes activation function 1, AF-1); followed by the C-region which encodes the DNA binding domain (DBD); a linker region D and the C-terminal E region. The DE region encodes the ligand binding domain (LBD), and a transcriptional domain (in helix 12), denoted as activation function 2 (AF-2) \[[@r70]\].

The Rev-erb/NR1D subgroup contains two members, Rev-erbα (NR1D1;\[[@r81]\]) and Rev-erbβ (NR1D2;\[[@r83]; [@r82]\]). The Rev-erbs, and retinoid related orphan receptors (RORs; \[[@r84]; [@r47]\] bind as monomers to the consensus NR half-site motif, flanked by an 6bp AT-rich sequence (A/T)~6~ PuGGTCA, or as a homodimer to a direct repeat of the core motif separated by 2 bp. Although these receptors are closely related, and bind to the same motif, they function in an opposing manner. The NR1D subgroup function as dominant transcriptional silencers, and they repress trans-activation mediated by RORα \[[@r4]\]. Interestingly, RORα activates Rev-erbα transcription \[[@r76]; [@r99]\], and Rev-erbα represses its own transcription \[[@r5]\].

Homology modeling of the putative LBDs of the NR1D subgroup suggested that the pocket is occupied by bulky side chains, and the small residual cavity could not "accommodate" a classical ligand. Concordantly, NR1D1 and 2 are the only members of the superfamily that do not encode helix 12 and an AF-2 domain \[[@r77]\]. However, the existence of a novel small molecular regulator cannot be precluded. Molecular modeling also revealed a very hydrophobic surface due to the absence of H12, exposing residues from H3, loop 3-4, H4, and H11 that mediate corepressor recruitment.

Rev-erbs and lipid metabolism
=============================

Rev-erbα has been shown to be involved in repressing rat apoA1 gene expression \[[@r9]\]. *in vivo* studies have shown that apoA1 reduces free cholesterol accumulation in atherosclerotic lesions of ApoE-deficient mice. Moreover, human Rev-erbα and β specifically repress apoCIII gene expression in rats \[[@r12]\] and humans \[[@r13]\]. ApoCIII is a component of HDL and VLDL that regulates triglyceride levels and lipoprotein lipase activity. In this context Rev-erbα null mutant mice \[[@r100]\] have elevated VLDL triglyceride and apoCIII levels \[[@r13]\]. It is interesting to note that plasma triglyceride and apoC-III protein concentrations in staggerer (sg/sg) mice, homozygous for a deletion in the RORα gene, were significantly lower than in wild type littermates \[[@r47]\]. This is in agreement with the repression and activation of apoCIII gene expression by Rev-erbα and RORα, respectively. Moreover, it highlights the regulatory crosstalk between Rev-erbα and RORα in the context of the blood lipid profile.

Hypolipidemic fibrate drugs increase Rev-erbα expression in human liver cells \[[@r96]\]. Interestingly, the fibrate mediated activation occurs at the transcriptional level in a PPARα dependent manner. The mechanism involves a previously characterized Rev-erbα response element; a unique DR2 element whose 5' region is flanked by AT-rich sequence. Rev-erbα and PPARα compete for binding to this response element in the Rev-erbα promoter. Moreover, Rev-erbα has been shown to modulate hydratase-dehydrogenase expression, a key gene involved in peroxisomal β-oxidation pathway through repression of PPARα-dependent transactivation \[[@r109]\]. Similarly, the mechanisms involved direct binding to a PPRE, however, the Rev-erbα and PPARα binding characteristics to the response element were distinct. Furthermore, fibrates regulate apoA1 gene expression in a species specific manner. For example, fibrates increase and decrease apoA1 expression in humans and rats respectively. Firstly, the repression of apoA1 expression in fibrates is due to a 3 nucleotide difference in the rat promoter that produces a non-functional PPARα response element. Secondly, the rat but not the human promoter harbors a Rev-erbα response element that mediates Rev-erbα dependent repression in the presence of fibrates. These studies underscore the crosstalk between Rev-erbα and PPARα in the control of lipid homeostasis.

Rev-erbα and β are regulated in a biphasic manner during DMI (Dexamethasone/IBMX/Insulin) and rosiglitazone induced adipocyte differentiation \[[@r46]; [@r118]; [@r90]\]. Rosiglitazone induced adipogenesis involves PPAR-γ mediated induction of Rev-erbα mRNA expression. In agreement, exogenous expression of Rev-erbα in 3T3-L1 cells promoted adipogenic differentiation \[[@r122]\]. In contrast, Rev-erbα and β antagonistically regulate mammalian muscle differentiation and their expression levels decrease during myogenesis \[[@r7]; [@r55]\].

*In vivo* studies in mice suggest that Rev-erbα is preferentially expressed in fast-twitch type IIB and intermediate typeIIA fibers. Moreover, in slow twitch (type I) soleus muscle of Rev-erbα homozygous and heterozygous null mutant mice, there is a significant increase in the expression of the β/slow myosin heavy chain (MyHC) isoform \[[@r116]\]. Type IIB fast fibers utilize glycolysis, in contrast, type IIA combine fast twitch glycolytic capacity with aerobic metabolism. Type I fibers are dependent on the aerobic metabolism of fatty acids. The expression of Rev-erbα in energy demanding tissues, the fiber specific expression characteristics, and the effect of the null mutation on the muscle phenotype suggest a role in metabolism.

In this context, it has been shown that ectopic Rev-erbβΔE (that lacks the LBD) expression in skeletal muscle cells attenuated the expression of many genes involved in fatty acid/lipid absorption (including FAT/CD36, FABP-3 and -4), and an expected increase in RORα expression \[[@r40]\]. Interestingly, these authors reported a dramatic decrease in the expression of the mRNA encoding myostatin, a TGF-β family member that plays a crucial role in regulating muscle and adipose mass \[[@r114]\]. Myostatin -/- mice have increased skeletal muscle mass (from muscle hypertrophy and hyperplasia) accompanied by decreased adiposity. McPherron and Lee reported that the introduction of the myostatin mutation in mouse models of obesity and diabetes, suppressed fat accumulation and hyperglycemia \[[@r34]\]. The Rev-erbα and Rev-erbβ target genes and tissues are schematically depicted in [Figure 1](#fig1){ref-type="fig"}.

Rev-erbs and circadian rhythm
=============================

Rev-erbα is involved in circadian timing in brain and liver tissue, and regulates BMAL1, and to a lesser extent CLOCK expression (see [Figure 2](#fig2){ref-type="fig"}) \[[@r103]; [@r102]\]. Rev-Erbα itself is driven directly by the molecular oscillator, it is activated by the BMAL1-CLOCK heterodimer, and repressed by PERIOD1/2 and CRYPTOCHROME1/2 proteins \[[@r87]; [@r65]\]. It is interesting to note that Rev-erbα and RORα opposingly regulate Bmal1 expression and are an integral component of a complex transcriptional feedback loop (see [Figure 2](#fig2){ref-type="fig"}) \[[@r103]; [@r93]; [@r91]; [@r102]\]. The amplitude of Bmal1, Clock, and Cry1 mRNA oscillations are significantly attenuated in Rev-erbα -/- mice. Rev-erbα has been shown to influence period length and phase shifting. Schibler and colleagues demonstrated that Rev-erbα -/- mice kept under constant darkness and constant light conditions had a shorter period length compared to wild-type animals \[[@r87]\]. Curiously, the maintenance of circadian pacemaker by Rev-erbα is also conserved in other organisms such as zebrafish \[[@r101]\]. Laudet and colleagues have hypothesized that Rev-erbα can function as integrator of circadian and physiological events \[[@r65]\]. The literature provides copious examples of circadian regulation of blood pressure, and hypertensive fluctuations associated with cardiovascular disease \[[@r86]; [@r85]\]. Furthermore, aberrant sleep cycles in humans lead to increased secretion of proinflammatory cytokines (for example TNFα and IL-6) \[[@r73]\] and reduced cortisol secretion \[[@r74]\]. In this context, mice treated with prednisolone repressed Rev-erbα and Bmal1 expression \[[@r121]\]. Very recently, Yin et al. demonstrated that glycogen synthase kinase 3 (GSK3)-mediated phosphorylation of Rev-erbα and stabilizes the expression of the nuclear receptor \[[@r120]\]. Excitingly, they went on to demonstrate that lithium treatment (commonly used to treat bipolar disorder) leads to proteosomal degradation of Rev-erbα and induction of Bmal 1. This process is mediated by lithium induced inhibition of GSK3. Finally, a report from Cermakian and colleagues also highlights that Rev-erbβ can regulate circadian transcription of the Bmal1 gene \[[@r113]\].

Rev-erbs and inflammation
=========================

Lipopolysaccharide induced activation of bone marrow derived macrophages induces biphasic regulation of Rev-erbβ \[[@r115]\]. Recent studies have shown that inflammatory cytokines play crucial roles in endothelial and smooth muscle cell responses in diseases associated with the vasculature. Vascular smooth muscle cells over-expressing Rev-erbα induced NF-κB mediated trans-activation (and p65 translocation). In addition, increased expression of the pro-inflammatory cytokines IL-6 and COX-2 was observed \[[@r60]\]. Concordantly, ectopic expression of RORαin human smooth muscle cells inhibits TNFα mediated induction of IL-6, IL-8, and COX-2 expression through induction of IκBα \[[@r117]\]. The attenuation of Rev-erbβ expression/function in skeletal muscle cells has been reported to induce IL-6 mRNA expression. Paradoxically, this was associated with increased expression of RORα and IκBα\[[@r40]\]. IL-6 is an exercise induced myokine that induces lipolysis in adipose tissue, and suppresses TNFα production. The increased expression of IL-6 is consistent with decreased myostatin expression. For example, it has been reported that IL-6 deficiency leads to late-onset obesity \[[@r79]\], whereas myostatin deficiency leads to the reduced accumulation of body fat \[[@r34]\]. Therefore, the inverse correlation between IL-6 and myostatin expression after attenuation of Rev-erbβ expression is in concordance with the reported phenotypic effects of these proteins. The studies above highlight the emerging role of Rev-erbs in the inflammation cascade.

Concluding remarks and future directions
========================================

Molecular modeling suggests the cavities in the LBDs of the NR1D subgroup are occupied by bulky side chains. This indicates that pharmacological manipulation of this orphan NR subgroup by agonists and antagonists in the near future may present technical challenges. However, a recent report from Reinking et al \[[@r107]\] has shown that the ligand binding pocket of E75, a Drosophila orthologue of human Rev-erbα is tightly bound by heme. In recent years, various heme containing molecules have been identified to regulate lipid homeostasis. For example, heme containing neuronal nitric oxide synthase regulates genes involved in the lipogenesis pathway \[[@r119]\]. Curiously, Reinking and colleagues also identified E75 as a potential gas sensor and that CO or NO bind to E75 to interfere with E75 mediated repression of DHR3, a Drosophila orthologue of human RORα, see [Figure 3](#fig3){ref-type="fig"}). Moreover, heme, NO and CO are important regulatory molecules in mammalian circadian clocks (reviewed in \[[@r110]\]). Recently, cholesterol/cholesterol sulphate and all-trans retinoic acid have been identified as RORα and RORβ agonists, respectively \[[@r105]; [@r106]; [@r104]\]. In summary, these studies suggest that identification of novel synthetic small molecule regulators for the NR1D subgroup by contemporary chemistry in the near future is possible.

Further insights into the function of the NR1D subgroup in the short term will require targeted genetic analysis of both Rev-erbα and β in specific tissues and organs. Cell specific attenuation of the NR1D subgroup (by Cre-Lox and/or transgenic techniques) in the major mass tissues (including skeletal muscle, liver and adipose tissue) will provide novel insights into the physiological role of these orphan NRs in metabolism.

The NR1D subgroups are transcriptional silencers, and identification of target genes is certainly an area requiring additional study. Current studies indicate Rev-erb signaling impacts on RORα and PPARα-mediated control of inflammation and metabolism. Furthermore, it is increasingly apparent that Rev-erbα is an integral component of complex transcriptional feedback loops that are involved in circadian control. Complete elucidation of the pathophysiologically relevant targets of the Rev-erbs and the crosstalk with other NR signaling pathways in a cell/organ specific context will provide unique insights into the links between metabolism, inflammation and the circadian cycle in homeostasis.

We apologize to those authors whose work was not cited in the pursuit of brevity. We thank Michael Pearen for his help in preparing Figure 1. SR holds an University of Queensland Postgraduate Scholarship. GEOM is a Principal Research Fellow of the National Health and Medical Research Council of Australia (NHMRC), and this study was supported by an NHMRC project grant.

apoA1

:   apolipoprotein A1

apoCIII

:   apolipoprotein CIII

apoE

:   apolipoprotein E

BMAL1

:   Brain and Muscle Arnt-like protein-1

bp

:   base pair(s)

CO

:   carbon-monoxide

COX-2

:   cyclooxygenase 2

DR2

:   direct repeat 2

FABP

:   fatty acid binding protein

FAT/CD36

:   fatty acid translocase

HDL

:   high density lipoprotein

IL-6

:   Interleukin-6

IκBα

:   Inhibitor of NF;

LBD

:   ligand binding domain

NFκB

:   nuclear factor κB

NO

:   nitric-oxide

NR

:   nuclear receptor

PPAR

:   peroxisome proliferators-activated receptor

ROR

:   RAR-related orphan receptor

TGF-β

:   transforming growth factor β

TNF-α

:   tumor necrosis factor α

VLDL

:   very low density lipoprotein

Figures and Tables
==================

![Target genes of the NR1D subgroup.\
"Rev-erbs" regulate gene expression events in various species and tissues. Genes listed include primary and secondary targets that have been documented in the literature.](nrs04009.f1){#fig1}

![Cross-talk between Rev-erbα and RORα signaling in circadian gene regulation.\
Rev-erbα and RORα mutually regulate circadian Clock genes. Dysregulation in these pathways leads to chronic disease state such as metabolic syndrome.](nrs04009.f2){#fig2}

![A speculative model for ligand-dependent Rev-erbα modulation in mammals.\
Like Drosophila, endogenous molecules such as heme and diatomic gases could possibly bind to Rev-erbα and activate/modulate its ability to trans-repress RORα and other gene expression events.](nrs04009.f3){#fig3}
